Syntara Dirección

Dirección controles de criterios 3/4

Syntara's El consejero delegado es Gary Phillips , nombrado en Mar 2013, tiene un mandato de 11.08 años. la remuneración anual total es A$753.60K , compuesta por 61.3% salario y 38.7% primas, incluidas acciones y opciones de la empresa. posee directamente 0.028% de las acciones de la empresa, por valor de €4.20K . La antigüedad media del equipo directivo y del consejo de administración es de 11.4 años y 6.5 años respectivamente.

Información clave

Gary Phillips

Chief Executive Officer (CEO)

AU$753.6k

Compensación total

Porcentaje del salario del CEO	61.3%
Permanencia del CEO	11.1yrs
Participación del CEO	0.03%
Permanencia media de la dirección	11.4yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gary Phillips en comparación con los beneficios de Syntara?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$18m
Jun 30 2023	AU$754k	AU$462k	-AU$11m
Mar 31 2023	n/a	n/a	AU$2m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	AU$2m
Jun 30 2022	AU$628k	AU$451k	-AU$2m
Mar 31 2022	n/a	n/a	-AU$16m
Dec 31 2021	n/a	n/a	-AU$12m
Sep 30 2021	n/a	n/a	-AU$1m
Jun 30 2021	AU$683k	AU$444k	-AU$3m
Mar 31 2021	n/a	n/a	AU$5m
Dec 31 2020	n/a	n/a	-AU$4m
Sep 30 2020	n/a	n/a	-AU$13m
Jun 30 2020	AU$559k	AU$440k	-AU$14m
Mar 31 2020	n/a	n/a	-AU$21m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$18m
Jun 30 2019	AU$613k	AU$433k	-AU$20m
Mar 31 2019	n/a	n/a	-AU$27m
Dec 31 2018	n/a	n/a	-AU$12m
Sep 30 2018	n/a	n/a	-AU$22m
Jun 30 2018	AU$776k	AU$424k	AU$6m
Mar 31 2018	n/a	n/a	AU$10m
Dec 31 2017	n/a	n/a	-AU$1m
Sep 30 2017	n/a	n/a	AU$7m
Jun 30 2017	AU$799k	AU$423k	-AU$18m

Compensación vs. Mercado: La compensación total de Gary ($USD499.14K) es aproximadamente el promedio para empresas de tamaño similar en el mercado German ($USD391.56K).

Compensación vs. Ingresos: Garyha aumentado mientras la empresa no es rentable.

CEO

Gary Phillips (62 yo)

11.1yrs

Permanencia

AU$753,599

Compensación

Mr. Gary Jonathan Phillips, BPharm, MBA, serves as Independent Non-Executive Director at Arovella Therapeutics Limited since July 1, 2022. He has been Chief Executive Officer and Managing Director of Synta...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gary Phillips	CEO, MD & Director	11.1yrs	AU$753.60k	0.028% A$ 3.4k
David McGarvey	CFO & Company Secretary	21.3yrs	AU$555.57k	0.087% A$ 10.7k
Wolfgang Jarolimek	Head of Drug Discovery	11.7yrs	AU$541.14k	0.14% A$ 17.7k
Kristen Morgan	Head of Medical & Regulatory Affairs - Alliance Management	no data	AU$323.75k	0.027% A$ 3.4k
Jana Baskar	Chief Medical Officer	1.8yrs	AU$429.39k	0.034% A$ 4.1k
Cameron Billingsley	General Counsel	no data	sin datos	sin datos

11.4yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: A3E4P8El equipo directivo de la empresa es veterano y experimentado (11 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gary Phillips	CEO, MD & Director	11.1yrs	AU$753.60k	0.028% A$ 3.4k
Neil Graham	Non-Executive Director	3.9yrs	AU$85.23k	sin datos
Malcolm McComas	Independent Director	20.8yrs	AU$115.23k	0.21% A$ 25.4k
Alan Robertson	Member of Scientific Advisory Board	no data	AU$711.06k	sin datos
Simon Green	Independent Non-Executive Director	1.3yrs	AU$37.96k	0.076% A$ 9.3k
Darren Kelly	Member of Scientific Advisory Board	6.5yrs	sin datos	sin datos
Kathleen M. Metters	Member of Scientific Advisory Board & Independent Chair	6.8yrs	AU$85.23k	0.0017% A$ 205.8
Andrew Boyle	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jacob George	Member of Scientific Advisory Board	no data	sin datos	sin datos
Carol Pollock	Member of Scientific Advisory Board	no data	sin datos	sin datos
Waradana Malitha De Silva	Non-Executive Director	1.3yrs	AU$32.40k	0.027% A$ 3.3k

6.5yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de A3E4P8 se considera experimentada (6.2 años de antigüedad promedio).

Syntara Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Less than half of directors are independent

Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022

Recent updates

No longer forecast to breakeven

New major risk - Shareholder dilution

Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.

New major risk - Financial position

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

Less than half of directors are independent

Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings released: EPS: AU$0 (vs AU$0.003 loss in FY 2022)

Forecast to breakeven in 2026

New minor risk - Financial data availability

Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Pharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022

Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial

Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study

Pharmaxis Ltd Updates on Phase 2 Study of the Pharmaxis Drug Discovery PXS4728

Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.007 loss in FY 2021)

Pharmaxis Ltd to Report Fiscal Year 2022 Final Results on Aug 23, 2022

Pharmaxis Ltd Announces Resignation of Will Delaat as Non Executive Director

Full year 2022 earnings released

Pharmaxis Limited Announces the Appointment of Dr. Jana Baskar as Chief Medical Officer

Pharmaxis Ltd, Annual General Meeting, Jul 11, 2022

Pharmaxis Ltd to Report Fiscal Year 2022 Results on Aug 11, 2022

Less than half of directors are independent

Second quarter 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd Announces First Patients Dosed in PXS Scar Reduction Trial

Independent Chairman of the Board recently bought €71k worth of stock

First quarter 2022 earnings released: AU$0.007 loss per share

Pharmaxis Ltd Announces Results of Data Analysis from the Second of Three Stages in Its Phase 1C Clinical Trial (MF-101) Studying Potential New Treatment for the Bone Marrow Cancer Myelofibrosis

Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer

Pharmaxis Ltd announced that it expects to receive AUD 4.366891 million in funding from Karst Peak Capital Limited, BVF Partners, L.P.

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Pharmaxis Exports CF Drug to US

Second quarter 2021 earnings released

Revenue misses expectations

Pharmaxis Receives USD 7 Million Milestone from Chiesi

Pharmaxis Ltd, Annual General Meeting, Nov 03, 2021

Pharmaxis to Present at Proactive CEO Investor Session

First quarter earnings released

Pharmaxis Ltd Auditor Raises 'Going Concern' Doubt

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad